Terms: = Brain cancer AND ER, estrogen receptor AND Treatment
450 results:
1. Design and methods of the mobile assessment of cognition, environment, and sleep (MACES) feasibility study in newly diagnosed breast cancer patients.
Derbes R; Hakun J; Elbich D; Master L; Berenbaum S; Huang X; Buxton OM; Chang AM; Truica CI; Sturgeon KM
Sci Rep; 2024 Apr; 14(1):8338. PubMed ID: 38594369
[TBL] [Abstract] [Full Text] [Related]
2. Human Epidermal Growth Factor receptor 2-Low Breast cancer brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
Chehade R; Nofech-Mozes S; Plotkin A; Fan KY; Das S; Sahgal A; Moravan V; Jerzak KJ
JCO Precis Oncol; 2024 Mar; 8():e2300487. PubMed ID: 38547418
[TBL] [Abstract] [Full Text] [Related]
3. Protecting the brain: Novel Strategies for Preventing Breast cancer brain Metastases through Selective estrogen receptor β Agonists and In Vitro Blood-brain Barrier Models.
Kirchner J; Völker E; Shityakov S; Saji S; Förster CY
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542355
[TBL] [Abstract] [Full Text] [Related]
4. estrogen-receptor status determines differential regulation of α1- and α2-adrenoceptor-mediated cell survival, angiogenesis, and intracellular signaling responses in breast cancer cell lines.
Priyanka HP; Pratap UP; Nair RS; Vasantharekha R; ThyagaRajan S
Med Oncol; 2024 Mar; 41(5):92. PubMed ID: 38526769
[TBL] [Abstract] [Full Text] [Related]
5. Systematic identification of a synthetic lethal interaction in brain-metastatic lung adenocarcinoma.
Moon JW; Hong BJ; Kim SK; Park MS; Lee H; Lee J; Kim MY
Cancer Lett; 2024 Apr; 588():216781. PubMed ID: 38494150
[TBL] [Abstract] [Full Text] [Related]
6. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
[TBL] [Abstract] [Full Text] [Related]
7. Combination of Palbociclib and Endocrine Therapy in Hormone receptor-Positive and Human Epidermal Growth Factor receptor 2-Negative Metastatic Breast cancer With or Without brain Metastases.
Zhang Q; Lan X; Huang J; Xie X; Chen L; Song L; Bai X; Chen X; Jing H; Du C
Technol Cancer Res Treat; 2024; 23():15330338231206986. PubMed ID: 38233376
[TBL] [Abstract] [Full Text] [Related]
8. Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics.
Sokolov D; Sharda N; Banerjee A; Denisenko K; Basalious EB; Shukla H; Waddell J; Hamdy NM; Banerjee A
Curr Pharm Des; 2024; 30(1):31-47. PubMed ID: 38151840
[TBL] [Abstract] [Full Text] [Related]
9. A novel treatment to enhance survival for end stage triple negative breast cancer using repurposed veterinary anthelmintics combined with gut‑supporting/immune enhancing molecules.
Iragavarapu-Charyulu V; Shakya R; Robinson P; Guzmán E; Tyulmenkova A; Pino JL; Isgor C
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38131223
[TBL] [Abstract] [Full Text] [Related]
10. Palazestrant (OP-1250), A Complete estrogen receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast cancer Models as Monotherapy and in Combination.
Parisian AD; Barratt SA; Hodges-Gallagher L; Ortega FE; Peña G; Sapugay J; Robello B; Sun R; Kulp D; Palanisamy GS; Myles DC; Kushner PJ; Harmon CL
Mol Cancer Ther; 2024 Mar; 23(3):285-300. PubMed ID: 38102750
[TBL] [Abstract] [Full Text] [Related]
11. Dual targeting agent Thiotert inhibits the progression of glioblastoma by inducing ER stress-dependent autophagy.
Dong J; Qian Y; Zhang W; Wang Q; Jia M; Yue J; Fan Z; Jiang Y; Wang L; Wang Y; Huang Z; Yu L; Wang Y
Biomed Pharmacother; 2024 Jan; 170():115867. PubMed ID: 38101281
[TBL] [Abstract] [Full Text] [Related]
12. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Watanabe S; Furuya N; Nakamura A; Shiihara J; Nakachi I; Tanaka H; Nakao M; Minato K; Seike M; Sasaki S; Kisohara A; Takeuchi S; Honda R; Takamura K; Kagamu H; Yoshimura K; Kobayashi K; Kikuchi T
Eur J Cancer; 2024 Jan; 197():113469. PubMed ID: 38061214
[TBL] [Abstract] [Full Text] [Related]
13. Chinese herb related molecules Catechins, Caudatin and Cucurbitacin-I inhibit the proliferation of glioblastoma by activating KDELR2-mediated endoplasmic reticulum stress.
Xia F; Sun S; Li S; Jiang W; Xia L; Wang H; Chen X
Biochem Biophys Res Commun; 2023 Dec; 687():149196. PubMed ID: 37939504
[TBL] [Abstract] [Full Text] [Related]
14. Predicting diagnosis and survival of bone metastasis in breast cancer using machine learning.
Zhong X; Lin Y; Zhang W; Bi Q
Sci Rep; 2023 Oct; 13(1):18301. PubMed ID: 37880320
[TBL] [Abstract] [Full Text] [Related]
15. A Web-based Prediction Model for Early Death in Patients With Metastatic Triple-negative Breast cancer.
Pan WK; Ren SY; Zhu LX; Lin BC
Am J Clin Oncol; 2024 Feb; 47(2):71-80. PubMed ID: 37871164
[TBL] [Abstract] [Full Text] [Related]
16. Predicting Patterns of Distant Metastasis in Breast cancer Patients following Local Regional Therapy Using Machine Learning.
Shiner A; Kiss A; Saednia K; Jerzak KJ; Gandhi S; Lu FI; Emmenegger U; Fleshner L; Lagree A; Alera MA; Bielecki M; Law E; Law B; Kam D; Klein J; Pinard CJ; Shenfield A; Sadeghi-Naini A; Tran WT
Genes (Basel); 2023 Sep; 14(9):. PubMed ID: 37761908
[TBL] [Abstract] [Full Text] [Related]
17. Treating brain metastases in metastatic breast cancer: outcomes after stereotactic radiosurgery examined in a retrospective, single-center cohort analysis.
Depner JF; Berg T; Ejlertsen B; Andreasen LW; Møller S; Maraldo MV
Acta Oncol; 2023 Nov; 62(11):1502-1510. PubMed ID: 37750329
[TBL] [Abstract] [Full Text] [Related]
18. 4-Phenylbutyrate promoted wild-type γ-aminobutyric acid type A receptor trafficking, reduced endoplasmic reticulum stress, and mitigated seizures in Gabrg2
Shen W; Flamm C; Delahanty AJ; Casteel E; Biven M; DeLeeuw MB; Poliquin S; Nwosu G; Randhave K; Kang JQ
Epilepsia; 2024 Jan; 65(1):204-217. PubMed ID: 37746768
[TBL] [Abstract] [Full Text] [Related]
19. Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
Medina EJ; Zohdy YM; Porto E; Revuelta Barbero JM; Bray D; Maldonado J; Rodas A; Mayol M; Morales B; Neill S; Read W; Pradilla G; Ioachimescu A; Garzon-Muvdi T
Front Endocrinol (Lausanne); 2023; 14():1195792. PubMed ID: 37529607
[TBL] [Abstract] [Full Text] [Related]
20. Prognosis of breast cancer patients with brain metastasis treated with radiotherapy.
Simonsen MK; Vrou Offersen B; Jensen AB
Acta Oncol; 2023 Aug; 62(8):871-879. PubMed ID: 37498539
[TBL] [Abstract] [Full Text] [Related]
[Next]
